Our Therapeutic Areas
Hematology
The pro-hemostatic aptamer BT200 is now entering Phase 3 for hereditary bleeding disorders.
Gastroenterology
Aptamer with high affinity and specificity for IL23 is currently being evaluated for use in IBD as an orally administered, topical enteric-selective immunomodulator.
Dermatology
Aptamer with high affinity and specificity for IL23 is currently being evaluated for use in autoimmune skin disease as a topical, selective, immunomodulator with locally restricted activity.
Oncology
Aptamers with high affinity and specificity for certain innate immune cell surface receptors, vascular growth factors, etc. and that can be configured as bi-specific agents or for use as Aptamer-Mediated Drug Conjugates.
Contact
© 2023 Guardian Therapeutics. All rights reserved.
Welcome to the Guardian Therapeutics and Band Therapeutics website. We do not use any cookies or other technologies on this website, except those that are strictly necessary to enable normal functioning of this web page. View our data protection statement.
Headquarters
Guardian Therapeutics
101 Hartwell Avenue
Suite 2
Lexington, MA 02421
+1 (781) 918-6580
General Inquiries:
info@guardian-rx.com
Business Development Inquiries: businessdevelopment@guardian-rx.com